The fixed dose of 1,400 mg subcutaneous (SC) rituximab predicted by using stage 1 results was confirmed to have noninferior Ctrough levels relative to IV rituximab 375 mg/m2 dosing during maintenance, with a comparable safety profile in patients with follicular lymphoma. Additional investigation will be required to determine whether the SC route of administration for rituximab provides equivalent efficacy compared with that of IV administration.

READ FULL ARTICLE Curated publisher From Ascopubs